Industry Insights
Peptide therapeutics market is expected to grow over the forecast period owing to the increasing prevalence of cancer and other various metabolic diseases. The other growth drivers of this market are introduction of technological advancements such as hybrid method of synthesis of peptides, lifestyle induced diseases such as obesity & diabetes, sophisticated healthcare infrastructure, increasing population and awareness. Peptides are referred as amide bonds which are linked with small chains of amino acid monomers. Peptides differ from protein on the basis of size. The presence of amino acids in peptides is less than 55 molecules. Peptides crunch themselves to some imitate such as receptor ligands and specific cell surface receptors. As peptides act on cell membrane, so it helps peptides in treating various diseases. As the market has a huge potential, thus various biotechnology and pharmaceutical industries are developing new peptides that can be used for various purposes. So these companies are actively investing in high R&D activities. Globally, cancer has been a foremost cause of death. As per the recent report published by WHO, it says that as of 2012, total number of cancer patient increased to 12.9 million and it is expected to be 16.2 million over the forecast period. Peptide therapeutics market is expected to boost owing to rise in metabolic diseases such as obesity & diabetes and further with growth in number of cancer patients. Various routes of administration and technologies in peptides have developed due to continuous R&D. In 2103, parenteral route of peptides has captured highest revenue share. Parenteral route is one of the conventional routes of administration. In 2013, long phase peptide synthesis has dominated the technology phase. The market serves the huge opportunity over the upcoming five years.
Technology Insight
Peptide therapeutics market is segmented on the basis of technology into HPPS, LPPS and SPPS. Among these SPPS technology held the largest market share in 2013 due to user friendliness and cost effective. In recent years HPSS technology has generated huge momentum and it is expected to be fastest growing technology over the forecast period.
Application Insights
Peptide therapeutics market is segmented on the basis of application into metabolic, cancer, CNS and CVS. In 2013, Peptide therapeutics had occupied most of the market share as it is used for treatment of cancer. Growing incidences of cancer and awareness is expected to drive the market over the forecast period.
Segment (Route of Administration) Insight
Peptide therapeutics market is segmented on the basis route of administration into oral, parenteral, mucosal and pulmonary. Among these parenteral routes held the largest market share in 2013, as it is used for a long time. Over the upcoming five years higher comfort level of patients is expected to drive the parenteral route.
Product Insight
Peptide therapeutics market is segmented on the basis product types into generic and innovative. Among these, innovative peptides held the largest market share in 2013, as it is cost effective as compared to generic peptides. With the help of technological advancement it is expected to grow over the forecast period.
Regional Insights
Geographically, the Peptide therapeutics market is studied by segmenting the market into North America, Europe, Asia Pacific and RoW. North America is dominating the whole market due to high per capita healthcare expenditure, sophisticated healthcare infrastructure, rising disposable income, various government or NGO’s initiatives and increasing geriatric population. Asia Pacific is expected to witness lucrative growth rate over the forecast period due to increasing population, government initiatives and growing economies.
Competitive Insights
The major market players in the Peptide therapeutics market are Bristol-Myers Squibb (BMS), Amylin Pharmaceuticals LLC, Bachem Holding AG, Roche, Amgen Inc., Peptisyntha, Ipsen, Eli Lilly and Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Merck & Co., Lonza Inc., Novartis AG, GlaxoSmithKline (GSK), PolyPeptide Group, Novo-Nordisk A/S, Pfizer Inc., Sanofi, and Teva Pharmaceuticals.
